What companies does RA Capital Management invest in?

RA Capital Management has 91 recorded portfolio companies, including Halda Therapeutics, Stipple Bio, Freenome.

What is RA Capital Management's AUM?

RA Capital Management manages approximately $10.0B in assets.

Is RA Capital Management actively investing?

RA Capital Management's most recent recorded investment was in Feb 2026, with 31 investments in the last 12 months.

PrivateMarketView

RA Capital Management key facts

RA Capital Management is a asset manager based in Boston, Massachusetts with 91 tracked portfolio companies.
Notable positions include Halda Therapeutics, Stipple Bio, Freenome.
PrivateMarketView records 251 deal participations by RA Capital Management.
RA Capital Management’s most recent recorded investment was in Feb 2026, one of 31 in the last 12 months and 77 over two years.
The team roster lists 66 people.
RA Capital Management reports $5.6B in regulatory assets under management across 6 private funds, per its SEC Form ADV (2026-03).

About RA Capital Management

Founded in 2004, RA Capital Management is an asset manager based in Boston, Massachusetts. The firm prefers to invest in healthcare, planetary health, and life science companies developing drugs, medical devices, services & research tools, and diagnostics, with a focus on those based in the United States and the European region. This firm is a Registered Investment Adviser (RIA).

Stages

Early Stage VCLater Stage VCPE Growth/ExpansionSeed RoundPreferred VerticalsHealthTechLife Sciences

Sectors

Diagnostic EquipmentOther Devices and SuppliesPharmaceuticals and BiotechnologySurgical DevicesTherapeutic DevicesGeographic PreferencesEuropeUnited StatesPreferred Deal TypesEarly Stage VCLater Stage VCPE Growth/ExpansionSeed RoundPreferred VerticalsHealthTechLife SciencesOther Investment PreferencesPrefers majority stakePrefers minority stakeWill lead on a deal

Geographies

EuropeUnited States

Investment focus

RA Capital Management invests at the early stage vc, later stage vc, pe growth/expansion, seed roundpreferred verticalshealthtech and life sciences stages, with a focus on Diagnostic Equipment, Other Devices and Supplies, Pharmaceuticals and Biotechnology, Surgical Devices, Therapeutic DevicesGeographic PreferencesEurope and United StatesPreferred Deal TypesEarly Stage VC, across Europe and the United States.

Its SEC Form ADV lists $5.6 billion in regulatory assets under management across 6 private funds (Mar 2026).

Investment activity

RA Capital Management joined 74 recorded rounds in the last two years (28 in the last 12 months), down from 117 in the two years before. By year: 11 in 2026, 46 in 2025 and 76 in 2024. Across all 251 recorded rounds, 109 were later-stage, 70 were early-stage and 10 were seed. 2 rounds landed in the last 90 days. RA Capital Management most often invests alongside Fidelity Management & Research Company (12 shared rounds) and Viking Global Investors (10 shared rounds). Most recently: Superluminal Medicines (Series B, Sep 2026) and Expedition Therapeutics (Series B, Aug 2026).

RA Capital Management portfolio at a glance

91 portfolio companies are on record for RA Capital Management, including Halda Therapeutics, Stipple Bio and Freenome. The book leans Drug Discovery (45), Biotechnology (7) and Discovery Tools (Healthcare) (4).

66 of the 91 carry a recorded valuation.

RA Capital Management team

66 people are on record at RA Capital Management: 11 associates, 10 managing partners, 9 principals, 7 analysts and 29 others. Senior names include Adam Kaye (Senior Managing Director), Andrew Levin Ph.D (Partner) and Brigid O'Brien (Managing Partner). 64 of them have a verified direct contact on file.

Is this your firm? Sign in with your work email to keep it current, or tell us what's wrong.

RA Capital Management at the SEC

Form ADV · 2026-03 · CRD 160174

Regulatory AUM: $5.6B
Private fund assets: $16.3B
Private funds: 6 · 5 venture, 1 hedge
Staff: 185
Registered office: BOSTON, MA
SEC status: Approved

Source: SEC Investment Adviser Public Disclosure, Form ADV (registered as RA CAPITAL MANAGEMENT, LP).

Free account

See more of the book

·The top 10 names in the book — of 91 recorded positions
·The 10 latest deals — of 251 rounds
·Watchlist + alerts for RA Capital Management's activity

Create free account

Membership and data by Private Market View

No card required

Portfolio

91 companies · priced for members

Company	Industry	Valuation	First invested	Role
Halda Therapeutics	Drug Discovery	▮	▮	▮
Stipple Bio	—	▮	▮	▮
Freenome	Decision/Risk Analysis	▮	▮	▮
+ 88 more companies · all 91, priced and dated or a free account shows the top 10 names — no card The whole book · Pro $99 a month Membership and data by Private Market View

RA Capital Management recent deals

251 recorded

Sep 2026Superluminal MedicinesSeries B▮

Aug 2026Expedition TherapeuticsSeries B▮

Feb 2026ILiAD BiotechnologiesLater Stage VC (Series B)▮

+ 248 more deals · amounts and lead flags are a member featureUnlock all 251 deals

Membership and data by Private Market View

RA Capital Management working numbers

the prospecting layer

Typical check

▮

Check sizes, follow-on behavior, holding periods — what a pitch needs. Pro.Unlock working numbers

Membership and data by Private Market View

Team

66 people on record — 64 with verified contacts

Partners, principals, and the people who answer a pitch. Pro members reveal contacts with credits.

See the team →

Frequently asked about RA Capital Management

What companies does RA Capital Management invest in?: RA Capital Management has 91 recorded portfolio companies, including Halda Therapeutics, Stipple Bio, Freenome.
What is RA Capital Management's AUM?: RA Capital Management manages approximately $10.0B in assets.
Is RA Capital Management actively investing?: RA Capital Management's most recent recorded investment was in Feb 2026, with 31 investments in the last 12 months.